Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence

Jie Qiao1,*,† and Huai L. Feng2,*,†

1Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100083, People’s Republic of China 2Department of Obstetrics and Gynecology, North Shore University Hospital, NYU School of Medicine, Manhasset, NY 11030, USA

*Correspondence address. Fax: +1-516-562-1754; E-mail: hfeng@nshs.edu (H.L.F.)/Fax: +1-86-10-62013283; E-mail: jie.qiao@263.net (J.Q.)

Submitted on February 18, 2010; resubmitted on June 10, 2010; accepted on June 18, 2010

TABLE OF CONTENTS

- Introduction
- Methods
- Extra-ovarian factors
  - FSH deficiency
  - Hypersecretion of LH
  - Hyperandrogenemia
  - Hyperinsulinemia
- Intra-ovarian factors
  - Epidermal growth factor family
  - Fibroblast growth factor family
  - Insulin-like growth factor family
  - Neurotrophin growth factor family
  - Transforming growth factor-β family
  - Vascular endothelial growth factor family
  - Cytokine family
  - Other microenvironment factors
- Concluding remarks

BACKGROUND: Polycystic ovary syndrome (PCOS) is a common metabolic dysfunction and heterogeneous endocrine disorder in women of reproductive age. Although patients with PCOS are typically characterized by increased numbers of oocytes retrieved during IVF, they are often of poor quality, leading to lower fertilization, cleavage and implantation rates, and a higher miscarriage rate.

METHODS: For this review, we searched the database MEDLINE (1950 to January 2010) and Google for all full texts and/or abstract articles published in English with content related to oocyte maturation and embryo developmental competence.

RESULTS: The search showed that alteration of many factors may directly or indirectly impair the competence of maturing oocytes through endocrine and local paracrine/autocrine actions, resulting in a lower pregnancy rate in patients with PCOS. The extra-ovarian factors identified included gonadotrophins, hyperandrogenemia and hyperinsulinemia, although intra-ovarian factors included members of the epidermal, fibroblast, insulin-like and neurotrophin families of growth factors, as well as the cytokines.

† Two equal first authors.
Introduction

Polycystic ovary syndrome (PCOS) is a common metabolic dysfunction and heterogeneous endocrine disorder in women of reproductive age (Franks, 1995; 2008; Knochenhauer et al., 1998; Diamanti-Kandarakis et al., 2008; Asunción et al., 2000; Azziz, 2004; Wood et al., 2007; Touli et al., 2009). It is characterized by a clustering of hyperandrogenism, hyperinsulinemia, hypersecretion of LH, menstrual dysfunction, hirsutism, infertility and pregnancy and neonatal complications (Franks, 1995; Moran and Teede, 2009; Stubbs et al., 2007; Touli et al., 2009). Women with PCOS undergoing IVF treatment have been well-described (Ludwig et al., 1999; Legro, 2001; Mulders et al., 2003; Heijnen et al., 2006; Sahu et al., 2008). Although PCOS patients are typically characterized by producing an increased number of oocytes, they are often of poor quality, leading to lower fertilization, cleavage and implantation rates, and a higher miscarriage number of oocytes, they are often of poor quality, leading to lower pregnancy and increased miscarriage rates, which are not genetically associated with an increased risk for embryonic aneuploidy (Weghofer et al., 2007). Hence, other factors, aside from chromosomal factors, are most likely associated with the significantly increased risk for pregnancy loss in patients with PCOS (Sagle et al., 1988; Carmina and Lobo, 1999; Wood et al., 2007; Weghofer et al., 2007). Impaired oocyte maturation and embryonic developmental competence in PCOS women is possibly linked with abnormal endocrine/paracrine factors, metabolic dysfunction and alterations in the intrafollicular microenvironment during folliculogenesis and follicle maturation (Franks et al., 2002; Dumesic et al., 2007b; Dumesic and Abbott, 2008; Wood et al., 2007). Therefore, a better understanding of how PCOS is related to abnormalities in extra- and intra-ovarian factor (Fig. 1, Table 1) and their impact on granulosa cell (GC)—oocyte interactions, oocyte maturation and potential embryonic developmental competence, will be crucial to improving fertility and optimizing clinical stimulation, thus enhancing pregnancy outcomes in women with PCOS undergoing IVF treatment.

Methods

For this review, we searched the database MEDLINE (1950 to January 2010) and GOOGLE for all full texts and/or abstract articles published in English; our own unpublished data were taken into account as well. Search terms included ‘oocyte’, ‘embryo’, ‘oocyte and embryo’, ‘oocyte and embryo quality’, ‘oocyte quality’, ‘embryo quality’, ‘fertilization’, ‘oocyte aneuploidy’, ‘embryo aneuploidy’, ‘oocyte abnormality’, ‘embryo abnormality’, ‘clinical issue’, ‘laboratory issue’, ‘IVF outcome’, ‘follicle fluid’, ‘follicle fluid hormone’, ‘follicle fluid and oocyte’, ‘follicle fluid and embryo’, ‘folliculogenesis’, ‘extra- and intra-ovarian factors’, ‘follicular fluid factors’ and ‘growth factors’ in PCOS. This search resulted in 1596 papers. Upon screening the results for applicable titles and/or abstracts, only articles correlating to PCOS and its relatives were selected for this review. In addition, we hand-searched references of relevant reviews, and conference abstracts, and included ongoing studies to locate other potentially eligible materials.

Extra-ovarian factors

Human folliculogenesis and follicle maturation are complicated developmental processes through which a mature follicle is differentiated from primordial follicles, yielding one mature follicle that is eventually selected to ovulate, releasing a mature oocyte. This developmental process can be disrupted by abnormal extra-ovarian endocrine factors, resulting in ovarian dysfunction. Complex endocrine disorders, such as FSH deficiency, hypersecretion of LH, hyperandrogenemia and hyperinsulinemia with insulin resistance, are responsible for the pathogenesis of PCOS, consequently increasing the risks of impaired oocyte developmental competence, implantation failure and miscarriage (Van der Spuy and Dyer, 2004; Dumesic et al., 2007a; Dumesic and Abbott, 2008; Boomsma et al., 2008).

FSH deficiency

FSH stimulates follicular growth and recruitment of immature follicles from the ovary. FSH is the major survival factor during folliculogenesis, when there is a delicate balance between recruitment and atresia of follicles. Human antral follicles between 2 and 5 mm become responsive to FSH, whereas slightly larger follicles between 6 and 8 mm acquire aromatase activity and potentially increase the estradiol (E2) levels (Dumesic and Abbott, 2008). With the concomitant rise in E2 and inhibit B, FSH levels then decline in the late follicular phase, and eventually only the most advanced and mature follicle is selected to proceed to ovulation. At the end of the luteal phase, there is a slight rise in the FSH level, which is very important in initiating the next ovulatory cycle (Erickson and Shimaski, 2001; Padhy et al., 2009). In contrast, PCOS patients show lower serum FSH levels as compared with normal cycles (Hillier, 1994). Consequently, FSH deficiency results in an increased accumulation of antral follicles between 2 and 8 mm (Franks et al., 2000, 2008). Clearly, the high number of smaller follicles indicates many have undergone premature arrest and failed to become the dominant follicle (Franks et al., 2008; Padhy et al., 2009). However, the developmental competence of oocytes collected from women with PCOS is normal, potentially leading to similar fertilization and normal cumulative pregnancy rates.

Key words: polycystic ovary syndrome / oocyte / fertilization / embryo / IVF

CONCLUSIONS: Any abnormality in the extra- and/or intra-ovarian factors may negatively affect the granulosa cell—oocyte interaction, oocyte maturation and potential embryonic developmental competence, contributing to unsuccessful outcomes for patients with PCOS who are undergoing assisted reproduction.
PCOS patients undergoing IVF commonly demonstrate elevated E2 levels, combined with a significantly higher number of oocytes retrieved, lower number of high-quality oocytes, poor fertilization rates, increased embryonic fragmentation, decreased percentage of blastocyst formation and lower implantation rates (Cano et al., 1997a, b; Urman et al., 2004). High E2 levels in PCOS patients may be detrimental to oocyte maturation and embryonic development (Hardy et al., 1995). In addition, recovery of immature oocytes followed by in vitro maturation (IVM) is a potentially useful treatment option for women with PCOS-related infertility. As an alternative approach, minimal or mild ovarian stimulation with FSH before oocyte collection has been applied in PCOS patients (Chian, 2004). Immature oocytes are then cultured in complex IVM culture medium plus 75 mIU/ml FSH + LH 75 mIU/ml for 24–48 h. ICSI is performed for mature oocytes. Despite the elevated number of immature oocytes obtained from PCOS patients with declining serum FSH levels (Dumesic et al., 2007b; Franks et al., 2008), oocyte maturation in vitro induced by extrinsic FSH and cumulus cell (CC)—oocyte interactions are crucial for the acquisition of oocyte developmental potential (Wynn et al., 1998; Dumesic et al., 2007b). Consequently, oocytes become fertilized embryos and potentially develop into the blastocyst stage (De La Fuente, 2006; Dumesic et al., 2007b). Results suggest that the cumulative pregnancy rate by IVM treatment in women with PCOS is comparable with that of other PCOS women undergoing conventional IVF (Child et al., 2001; Cha et al., 2005; Söderström-Anttila et al., 2005). However, recent studies have suggested that IVM has deleterious effects on the spindle organization and chromosomal configuration of oocytes from PCOS patients (Li et al., 2006; Navarro et al., 2007, 2009; Nichols et al., 2010), possibly explaining the reduced developmental competence of oocytes matured in vitro, compared with those matured in vivo. This may possibly contribute to the decline in the overall clinical outcome observed after IVM treatment (Li et al., 2006; Navarro et al., 2007, 2009).

**Hypersecretion of LH**

Women with PCOS typically have tonic hypersecretion of LH during the follicular phase of their cycles (Balen et al., 1993; Cano et al., 1997a, b; van der Spuy and Dyer, 2004). High LH levels have been associated with significant decreases in oocyte maturation and fertilization rates, and impaired embryo quality, consequently resulting in impaired pregnancy rates, and higher miscarriage rates (Adams et al., 1985; Stanger and Yovich, 1985; Hombur and Jacobs, 1989; Regan et al., 1990; Sengoku et al., 1997; Ludwig et al., 1999; Jabara and Coutifaris, 2003; Urman et al., 2004; van der Spuy and Dyer, 2004; Santos et al., 2010). Hypersecretion of LH during folliculogenesis may suppress FSH function, resulting in abnormal GC function by promoting premature GC luteinization and follicular anresia in small antral follicles from women with PCOS, causing premature oocyte maturation via inhibition of oocyte maturation inhibitors (Tesarik, 2003; van der Spuy and Dyer, 2004; Dumesic et al., 2007b; Franks et al., 2008), which all impair the quality of both oocyte and embryo (Tarlatzis and Grimbizis, 1997; Dumesic et al., 2002). LH may also activate premature meiotic processes by damaging the oocyte nucleus, leading to apoptosis via a receptor-coupled signal transduction system (Yoshimura and Wallach, 1987; Kurzawa et al., 2008). Disruption of the endocrine control of meiosis, resulting in impaired extrusion of the first polar body, may compromise the
Table I: Factors in serum and follicular fluid of patients with PCOS: impact on quality of oocyte and embryo, fertilization and outcome of pregnancy.

| Factors                              | Serum level | FF level | Oocyte quality | Fertilization rate | Embryo quality | Pregnancy rate | References                                                                 |
|--------------------------------------|-------------|----------|----------------|--------------------|----------------|----------------|---------------------------------------------------------------------------|
| Activin                              | ↓           | ↓        |                |                    |                |                | Norman et al. (2001), Erickson et al. (1995)                               |
| Anti-Müllerian hormone               | ↑           | ↑        | ↑ or ↓         | ↑ or ≈ or ↓        | ↑ or ≈         | ↑ or ≈         | Fallatt et al. (1997), Wang et al. (2007a, b), Mashiach et al. (2010), Desforges-Bullet et al. (2010) |
| Epidermal growth factor              | ↑           |          |                |                    |                |                | Volpe et al. (1991), Almahbobi et al. (1998), Artini et al. (2007)        |
| Fibroblast growth factor             | ↓ or ↑      | ↓ or ↑   | ≈ or ↓         | ≈ or ≈            | ≈              | ≈              | Hammadeh et al. (2003), Artini et al. (2006)                               |
| Follistatin                          | ↑           | ↑        |                |                    |                |                | Erickson et al. (1995), Norman et al. (2001), Eldar-Geva et al. (2001)    |
| Brain-derived neurotrophic factor    | ↑           |          |                |                    |                |                | Johnstone et al. (2008), Buyuk and Seifer (2008)                          |
| Bone morphogenetic protein-15       | ↑           | ↑        | ↑              | ↑                  |                |                | Wu et al. (2007a, b)                                                     |
| Estradiol                            | ↓           | ↓        | ↓              | ↓                  | ↓              |                | Berker et al. (2009), Amato et al. (2003)                                 |
| Follicular fluid meiosis-activating sterol | ↑      | ↑        | ≈              | ≈                  |                |                | Bokal et al. (2006)                                                      |
| Growth differentiation factor-9      | ↓           | ↓        |                |                    |                |                | Zhao et al. (2010)                                                       |
| Homocysteine                         | ↑           | ↑        | ↓              | ↓                  | ↓              |                | Nafiye et al. (2010), Berker et al. (2009)                                |
| Insulin-like growth factor-1 & 2     | ↓           | ↓        | ↓              |                    |                |                | Schoyer et al. (2007), Barreca et al. (1996), Eden et al. (1988)          |
| IGF binding proteins                 | ↑           | ↑        | ↓              |                    |                |                | Cataldo and Giudice (1992), Schoyer et al. (2007)                         |
| Interleukin 12                       | ↓           | ↓        | ↓              |                    |                |                | Gallinelli et al. (2003)                                                  |
| Interleukin 13                       | ↑           | ↓        | ↓              |                    |                |                | Gallinelli et al. (2003)                                                  |
| Inhibin A&B                          | ↓ or ≈     |          |                |                    |                |                | Welt et al. (2005), Magoffin and Jakimiuk (1998)                          |
| Corticotrophin-releasing hormone     | ↓           | ↓        |                |                    |                |                | Mastorakos et al. (1994)                                                  |
| Leptin                               | ↑           | ↑        | ↓              | ↓                  | ↓              |                | Mantzoros et al. (2000), Georgios et al. (2005), Li et al. (2007)          |
| Leukemia inhibitory factor           | ↓           | ↓        | ↓              |                    |                |                | Lédee-Bataille et al. (2001)                                              |
| Malondialdehyde                     | ↑           | ↑        | ↓              |                    |                |                | Yıldırım et al. (2007), Berker et al. (2009), Chattopadhyay et al. (2010) |
| Matrix metalloproteinase 2/9         | ↑ or ≈     |          |                |                    |                |                | Shalev et al. (2001), Lahav-Bratz et al. (2003)                           |
| Nerve growth factor                  | ↑ or ↓      |          |                |                    |                |                | Dissen et al. (2009); Buyuk and Seifer (2008)                             |
| Renin                                | ↓           | ↓        | ↑              | ↑                  |                |                | Bokal et al. (2003, 2004, 2005)                                           |
| Resistin                             | ≈           | ≈        | ↑              | ↑                  | ≈              | ≈              | Seow et al. (2005), Lu et al. (2005)                                      |
| Reactive oxygen species              | ↑           | ↓        | ↓              | ↓                  | ↓              |                | Chattopadhyay et al. (2010), Samanta et al. (2008)                        |
| Soluble Fas                          | ↓           | ↓        | ↓              |                    |                |                | Onalan et al. (2005)                                                     |
| sFas Ligand                          | ↑           | ↑        | ↓              |                    |                |                | Onalan et al. (2005)                                                     |

Continued
chromosomal normality of oocytes (Sengoku et al., 1997), possibly contributing to embryonic aneuploidy in women with PCOS (Weghofer et al., 2007). Errors in embryogenesis stemming from abnormal and premature oocyte exposure to increased LH stimulation may explain the elevated miscarriage rate in PCOS patients (Balen et al., 1993; Urman et al., 2004).

Hyperandrogenemia

Hyperandrogenemia is a common disorder in PCOS; it is multifactorial in origin, typically attributed to the ovary with substantial contributions from an adrenal source, and to a lesser extent adipose tissues (van der Spuy and Dyer, 2004; Nisenblat and Norman, 2009). Elevated free circulating levels of bioactive androgen results from either direct increases of ovarian production or an inhibition of hepatic synthesis of sex hormone-binding globin in PCOS patients with insulin resistance (Balen et al., 1995; van der Spuy and Dyer, 2004; Nisenblat and Norman, 2009). Increased androgen concentrations in the follicular fluid (FF) are associated with elevated serum LH levels, which may block dominant follicle development and cause follicular arrest and degeneration (Billig et al., 1993; Kurzawa et al., 2008). It has been suggested that high levels of androgen may have a negative impact on oocyte developmental competence (Brzynski et al., 2000; Teissier et al., 2000; Jabara and Coutifaris, 2003). Incubation of the oocyte with androgen in vitro is associated with decreased oocyte maturation rates (Tesarik and Mendoza, 1995). Data from an in vitro model suggest that testosterone exerts a strong inhibition of meiotic maturation and embryonic development in CC-free mouse oocytes, compared with CC-enclosed oocytes; this demonstrates that CCs can protect oocytes via local aromatase activity in human (Lauffer et al., 1984; Dumesic et al., 2007b) and mice (Anderiesz and Trounson, 1995). Such a CC function plays an important role in PCOS folliculogenesis, since small PCOS follicles are hyperandrogenic (Eden et al., 1990; Dumesic et al., 2007b) owing to intrinsically raised androgen biosynthesis by theca cells (Nelson et al., 2001). Further studies have suggested that elevated testosterone, either directly or indirectly, decreases the rates of IVM, fertilization and embryonic development (Dumesic et al., 2007b; Patel and Carr, 2008). The mechanism of testosterone activity within the oocyte may be related to decreased calcium oscillations, consequently inhibiting oocyte cytoplasmic maturation, with effects on meiotic maturation (Tesarik and Mendoza, 1995, 1997; Jabara and Coutifaris, 2003). In addition, elevated testosterone concentrations are associated with higher miscarriage rates in women with PCOS (van der Spuy and Dyer, 2004), suggesting that androgens may have a detrimental effect on folliculogenesis and endometrial function (Okon et al., 1998; Tuckerman et al., 2000).

Hyperinsulinemia

PCOS is an endocrine–metabolic disorder, closely tied to insulin resistance and a compensatory hyperinsulinemia. Metformin is the drug which has been studied most, and is administered to reduce fasting insulin, LH and free testosterone level, in an effort to restore menstrual cyclicity and fertility (Tang et al., 2010). It has been reported that insulin resistance is related to an increased miscarriage rate (Craig et al., 2002); several studies have suggested that metformin can effectively reduce pregnancy loss in women with PCOS (Glueck et al., 2001; Jacksonowitz et al., 2002; Kjortrup et al., 2004; Galal and Mitwally, 2009). Hyperinsulinemia may have preferentially impaired oocyte developmental competence, resulting in reduced rates of fertilization, embryonic development and implantation in PCOS patients with obesity (Hamilton-Fairley et al., 1992; Cano et al., 1997a, b; Wang et al., 2001; Wijeyaratne et al., 2002; Jabara and Coutifaris, 2003; Dumesic et al., 2002, 2007b; Dumesic and Abbott, 2008; Palep-Singh et al., 2007; Tian et al., 2007; Boomsma et al., 2008). Data from in vitro cell culture models suggest that co-incubation of insulin and FSH with mouse (Eppig et al., 1998) and bovine (Galal and Mitwally, 2009) oocytes promotes FSH-induced up-regulation of GC LH receptor mRNA expression (Dumesic et al., 2002; Tao and Yan, 2005; Diamanti-Kandarakis, 2008), inhibiting FSH stimulation of aromatase activity (Galal and Mitwally, 2009), thus reducing the percentage of fertilized oocytes that develop into blastocysts (Eppig et al., 1998; Dumesic et al., 2002, 2007b). Insulin may induce local androgen production, which results in oocytes of lower quality, post-maturity (Cano et al., 1997a, b). At the molecular level, insulin binds to its receptor, localized on GC and theca cells, and oocytes, to stimulate follicle

**Table I Continued**

| Factors                              | Serum level | FF level | Oocyte quality | Fertilization rate | Embryo quality | Pregnancy rate | References                        |
|--------------------------------------|-------------|----------|----------------|-------------------|----------------|----------------|-----------------------------------|
| Superoxide dismutase                 | ↓ or ≈      | ↓ or ≈  |                |                   |                |                | Sabatini et al. (2000), Bausenwein et al. (2010) |
| Total antioxidant capacity           | ↓           | ↓        | ↓              | ↓                 | ↓              | ↓              | Chattoopadhay et al. (2010) |
| Testosterone                         | ↑           | ↑        |                |                   |                |                | Brzynski et al. (1995), Teissier et al. (2000) |
| Tissue inhibitor of metallocproteinase-1 & 2 | ↓ or ≈      |          |                |                   |                |                | Lahav-Bratz et al. (2003), Shalev et al. (2001) |
| Tumor necrosis factor α              | ↑           | ↑        | ↓              | ↓                 | ↓              | ↓              | Amato et al. (2003), Wu et al. (2007a, b), Kim et al. (2009) |
| Vascular endothelial growth factor   | ↓ or ↑      | ↓ or ↑   | ↓              | ↓                 | ↓ or ≈         | ↓              | Bokal et al. (2004, 2005, 2009), Artini et al. (2006, 2009) |
| Visfatin                             | ↑           | ≈        |                |                   |                |                | Plati et al. (2009) |

All data are as compared with controls (patients without PCOS). ↑, increases or positive impact; ↓, decreases or negative impact; ≈, similar; blank, no data.
Intra-ovarian factors

Ovarian folliculogenesis is regulated by a fine balance between extra-and intra-ovarian factors (Artini et al., 2007). Oogenesis is profoundly dependent upon intra-ovarian factors, in particular follicle fluid factors (FFs) (Andresani et al., 1996; Hsieh et al., 2009; Padhy et al., 2009), which are positively related to levels of these factors in serum (Table 1). Any imbalance or dysfunction between extra- and intra-ovarian factors may result in abnormal folliculogenesis and oogenesis disorder (Frank et al., 2002, 2008; Artini et al., 2007). Recent studies suggest that the main FFs implicated in polycystic ovary folliculogenesis are members of the growth factor families, cytokines, inhibins and others (Franks et al., 2002; Artini et al., 2007; Diamanti-Kandarakis, 2008). Furthermore, a series of different serum factors, coupled with the intrafollicular fluid microenvironment, may directly impair oocyte developmental competence, should their balance be altered (Yen et al., 1993; Andresani et al., 1996; van der Spuy and Dyer, 2004; Artini et al., 2007; Padhy et al., 2009); this would consequently have a negative impact on the fertilization, embryonic development and outcome of pregnancy in PCOS patients (Table 1 and Fig. 1).

Epidermal growth factor family

Epidermal growth factor (EGF) is a soluble growth factor that plays an important role in the regulation of cell growth, proliferation and differentiation when bound to its receptor, EGFR (ErbB1, ErbB2-4; Hsieh et al., 2009). In the human ovary, EGF is found in the FF, regulating follicular development and oocyte meiotic maturation competence via EGFR signaling transduction system in the CCs (Westergaard and Andersen, 1989; Almahbobi et al., 1998; Jamnongjit et al., 2005; Hsieh et al., 2009). IVM studies show that exposure of the cumulus–oocyte complex (COC) to EGF stimulates CC expansion and improves the nuclear and cytoplasmic maturation of oocytes from the metaphase I (MI) to metaphase II (MII) stage in both cumulus–oocyte complex (COC) to EGF stimulates CC expansion and results in follicular arrest in PCOS patients (Artini et al., 2007). Therefore, it is hypothesized that a disruption in the regulatory mechanisms of EGF synthesis and/or physiological function mediated by EGFR may cause anovulatory infertility in women with PCOS (Almahbobi and Trounson, 1996; Almahbobi et al., 1998). Whether an elevated level of EGF in FF is correlated to oocyte quality and embryonic developmental competence is still unclear.

In addition, EGF-like factors, such as amphiregulin, epiregulin and betacellulin, are reportedly involved in oocyte maturation through autocrine and paracrine mechanisms (Ashkenazi et al., 2005; Shimada et al., 2006; Tse and Ge, 2009); however, the physiological function of EGF-like factors in PCOS remains unknown.

Fibroblast growth factor family

Fibroblast growth factors (FGFs) are a group of polypeptides that play a fundamental role in development, cell growth, tissue repair and transformation (Hammadeh et al., 2003). They are expressed in GC and theca cells of growing follicles, and are considered to be physiological regulators of FSH action (Artini et al., 2006, 2007); this may suggest a role for FGF in oocyte maturation by affecting surrounding follicular GC and theca cells (Skinner, 2005; Artini et al., 2007). A previous study shows that FGF levels in the serum and FF are lower in PCOS patients in comparison to patients with endometriosis and tubal factors (Hammadeh et al., 2003). In contrast, another research group reported that FGF concentrations are increased in the FF and serum of PCOS patients when compared with controls, leading to an inverse correlation with oocyte maturity (Artini et al., 2006, 2007); this supports speculation that FGF contributes to alterations in the intra-follicle environment, resulting in arrest of follicle development in patients with PCOS (Artini et al., 2007). Therefore, FGF alterations in the FF and serum remain controversial; the impact of EGF on oocyte maturation and embryonic development requires further elucidation in PCOS patients.

Insulin-like growth factor family

Insulin-like growth factors (IGFs) are multifunctional polypeptides with insulin-like activity. IGFs are part of a complex system used by cells to communicate with their physiological environment. This complex system consists of two surface-receptors (IGF1R and IGF2R), two receptor ligands (IGF-I and IGF-II), six high-affinity IGF binding proteins (IGFBP 1-6) and their specific proteases (Adashi, 1993; Frattali and Pessin, 1993; Yen et al., 1993; Erickson and Shimasaki, 2001; Artini et al., 2007).

Insulin-like growth factor-I/II and IGF binding proteins

IGFs and their binding proteins, IGFBPs, have important regulatory functions in ovarian follicular development (Yen et al., 1993; Artini et al., 2007). Circulating IGFs are produced in the liver, local IGF-I is secreted by theca cells whereas IGF-II is synthesized by GCs, and IGFBPs are present in the FF and expressed by GCs and theca cells (Yen et al., 1993; Erickson and Shimasaki, 2001; Artini et al., 2007). Although how IGFs are involved in the pathogenesis of PCOS remains unknown, the excess insulin concentrations and alterations in IGFs expression may be implicated (Yen et al., 1993). One recent report suggests that the FF IGF-I levels in PCOS women are elevated, although IGF-II and IGFBP-1 levels are lower than NOW (Artini et al., 2007). However, FF IGFBP-2 and -4 levels are significantly greater (Yen et al., 1993; Kwintkiewicz and Giudice, 2009); in contrast, IGFBP-1 is lower in PCOS patients, leading to follicular arrest (Artini et al., 2007). This evidence suggests that an altered IGF system is directly correlated to the oligo-ovulatory disorder of PCOS women (Kwintkiewicz and Giudice, 2009).
Women with PCOS have a higher FF IGFBP-3, but unaltered FF IGF-I levels (Amato et al., 1999). Research shows the levels of IGF-I, IGF-II and IGFBP-3 in mature follicles to be comparable between PCOS patients and controls; however, IGF-I levels in immature follicles in PCOS patients is decreased during ovarian stimulation, and this is associated with the generation of immature oocytes (Eden et al., 1998; Rabinovici et al., 1990; Franchimont et al., 1994; Pellegrini et al., 1995; Barreca et al., 1996; Dragisic et al., 2006; Schoyer et al., 2007). At the same time, IGFBP-3 levels are increased during stimulation, resulting in a greater likelihood of achieving pregnancy in PCOS patients (Schoyer et al., 2007). In infertile IVF patients, the ratio of IGF-I/IGFBP-1 in the serum and FF is significantly increased in women who become pregnant, highlighting the importance of oocyte quality and maturity during ovarian stimulation for IVF (Jimena et al., 1992; Artini et al., 1994; Kawano et al., 1997; Oosterhuis et al., 1998; Fried et al., 2003). Furthermore, results from in vitro culture models demonstrate that IGF-I can significantly increase embryonic development and blastocyst formation (Lighten et al., 1998; Liu et al., 1999; Fried et al., 2003). Hence, study of FF proteins may help to elucidate the roles of IGFs in GC function, meiotic maturity, oocyte chromosomal normality and embryonic developmental competence in PCOS patients.

**Neurotrophin growth factor family**

Brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), NT-3 and NT-4/5 are major members of the neurotrophin (NT) family of growth factors that are involved in development of the central and peripheral nervous systems (Levi-Montalcini, 1987; Snider, 1994; Buyuk and Seifer, 2008). NTs are not only involved in the nervous system, but also act on the ovaries of humans and other mammals (Seifer et al., 2002a, b; 2003; Buyuk and Seifer, 2008). NTs play a fundamental role in folliculogenesis and cytoplasmic competence of the oocyte (Buyuk and Seifer, 2008). Data from research using in vitro animal models suggest that co-incubation with BDNF promotes nuclear and cytoplasmic maturation of the oocyte, which are essential processes for successful oocyte and preimplantation embryo development (Da Silva et al., 2005; Kawamura et al., 2005). Evidence from some studies shows that increased FF BDNF and NGF levels are closely related to the pathology of women with PCOS (Bai et al., 2004; Johnstone et al., 2008; Dissen et al., 2009). Another report found that FF BDNF and NT-3 levels are increased, but FF NGF is decreased, in women with PCOS (Buyuk and Seifer, 2008) which may be indicative of the differential status of follicles in PCOS patients. Therefore, NT mechanisms in PCOS pathogenesis, especially their impact on oocyte and embryo developmental competence, need further clarification at different stages of follicle development.

**Transforming growth factor-β family**

Among the many intra-ovarian, factors, particular members of the transforming growth factor (TGF)-β family play an important biological role in follicle growth and oocyte development. These family members include anti-Müllerian hormone (AMH)/Müllerian inhibiting substance (MIS), activin, follistatin, inhibins, bone morphogenetic protein (BMP)-9 and growth differentiation factor (GDF)-9 (PieK et al., 1999; Artini et al., 2007; Dumesic et al., 2007b; Dumesic and Abbott, 2008). Under different physiological conditions, TGF-β family members may either promote or block ovarian follicle growth and/or differentiation of the GC–oocyte complex, which is also related to the pathogenesis of PCOS (van der Spuy and Dyer, 2004; Diamanti-Kandarakis, 2008; Dumesic and Abbott, 2008).

**Anti-Müllerian hormone/Müllerian inhibiting substance**

AMH, also known as Müllerian inhibiting factor (MIF), Müllerian inhibiting hormone (MIH) or MIS, is a homodimeric glycoprotein with a molecular weight of 140 kDa (Di Clemente et al., 2003; Artini et al., 2007). It inhibits the development of the Müllerian ducts in the male embryo (Behringer, 1994). AMH is expressed by GCs within ovaries of women of reproductive age, controlling the formation of primary follicles by inhibiting excessive follicular recruitment by FSH and therefore plays an important role in folliculogenesis (Weenen et al., 2004; Sadeu and Smitz, 2008). Some studies have demonstrated that AMH levels reflect some aspects of ovarian function, making AMH levels a potential marker for assessing conditions such as PCOS and premature ovarian failure (Visser et al., 2006; Sr-Petermann and King, 2007; Diamanti-Kandarakis, 2008; Dumesic and Abbott, 2008; Marca et al., 2009). Women with PCOS have elevated serum and FF AMH levels versus those of normal controls (Pigny et al., 2003; Laven et al., 2004; Artini et al., 2007), which is closely associated with increased development of antral follicles and follicular arrest in PCOS patients (Artini et al., 2007; Das et al., 2008; Diamanti-Kandarakis, 2008; Franks et al., 2008). Elevated AMH serum levels are directly correlated with increased testosterone and/or LH levels in women with PCOS, and profoundly impairing oocyte developmental competence and embryo quality (Tarlatzis and Grimbizis, 1997; Dumesic et al., 2002, 2007b; Patel and Carr, 2008; Franks et al., 2008). Also, elevated FF AMH concentrations in women with PCOS are linked to an increased percentage of immature oocyte and lower fertilization rates when compared with women with endometriosis or pelvic adhesions (Fallat et al., 1997); this is supported by evidence from the rat model as well (Takahashi et al., 1986). Recent complementary investigation suggests that increased FF AMH in women with PCOS may have harmful consequences on oocyte quality and maturation, via an unclear molecular mechanism, but does not have an effect on pregnancy rates (Desforges-Bullet et al., 2010).

In a contrasting study conducted among women with PCOS, results suggest that fertilization, implantation and clinical pregnancy rates are significantly better in the group with the highest FF AMH concentration than in any group with a lower concentration (Pabuccu et al., 2009). Additional reports reveal that women with PCOS who have lower FF AMH levels have similar rates of oocyte maturation, fertilization and embryonic development compared with NOW (Wang et al., 2007a, b; Mashiah et al., 2010). However, recent evidence suggests that FF AMH concentrations are only strongly and positively associated with oocyte quality and implantation rates, but not rates of oocyte fertilization, embryo cleavage and embryo morphology in NOW (Ebner et al., 2006; Fanchin et al., 2007; Marca et al., 2009). Still, others demonstrate that lower AMH levels are associated with poor oocyte quality, as supported by decreased fertilization and embryonic developmental rates, and increased miscarriage rates in IVF patients (Lekamge et al., 2007). Therefore, AMH may directly affect cytoplasmic maturation of the oocytes. Based upon all of the above
studies, variation in levels of AMH may indicate different physiological conditions during follicle development and oocyte maturation. Hence, AMH may not be a valuable predictor for success in NOW and women with PCOS undergoing assisted reproduction.

**Activin, follistatin and inhibin**

The activins, follistatin (FS) and inhibins are polypeptides which were originally isolated and characterized from ovarian FF. FS is an activin/inhibin binding protein produced by ovarian GCs, believed to act in an autocrine/paracrine manner to regulate growth and differentiation (Shimonaka et al., 1991; Findlay, 1993; Erickson et al., 1995); over-expression of FS has been associated with increased arrest of follicul development and decreased oocyte developmental competence (Erickson et al., 1995; Norman et al., 2001). Activins are preferentially secreted by these smaller follicles, promoting follicular development by increasing the GC response to FSH stimulation, decreasing androgen synthesis and enhancing oocyte maturation. Inhibins on the other hand, are produced by the dominant follicle and stimulate theca cell androgen production for E2 synthesis (Schwall et al., 1990; Klein et al., 2000; Knight and Glister, 2001; Dumesic et al., 2007b). In NOW, studies suggest that FF levels of inhibin A, inhibin B and activin A reflect changes in follicle size, but are not independent markers of the oocyte's ability to achieve fertilization and pregnancy (Fried et al., 2003; Wen et al., 2006).

An early study failed to demonstrate any correlation between inhibin A and B concentration in the FF and oocyte quality and fertilization rates (Lau et al., 1999). IVF patients with high FF inhibin A and B levels, measured on the day of oocyte retrieval, have better oocyte maturity and fertilization rates, and higher pregnancy rates (Dzik et al., 2000; Ocal et al., 2004). Another study reported that inhibin B levels in the FF are significantly correlated to embryo quality, but not oocyte quality (Change et al., 2002). Interestingly, no differences were found in the levels of FS and activin A in the FF from normal, atretic or polycystic ovaries (Erickson et al., 1995).

Increased FS/activin ratios (high FS and low activin A) are well-known contributors to the pathophysiology of PCOS (Eldar-Geva et al., 2001; Norman et al., 2001); both proteins have an effect on oocyte maturity and developmental competence, with activin enhancing post-fertilization development, and FS blocking this function (Norman et al., 2001). Elevated inhibin B levels are closely related to an elevated risk of developing PCOS (Magoffin and Jakimiuk, 1997; Anderson et al., 1998; Lockwood et al., 1998). In addition, studies have shown that inhibin A and B levels are significantly reduced in the FF of women with PCOS, when compared with FF levels of size-matched follicles from NOW (Lambert-Meserlian et al., 1997; Welt et al., 2005). Therefore, activin, FS and inhibins bring about intra-ovarian actions through paracrine/autocrine systems, playing an important role in maintaining folliculogenesis; their imbalance may be directly correlated to the pathogenesis of PCOS, consequently impairing oocyte maturity, embryo quality and pregnancy outcome.

**Growth differentiation factor-9 and bone morphogenetic protein-15**

GDF-9 and BMP-15 (also called as GDF-9b) are two closely related members of the TGF-β family of proteins and are highly expressed in growing and full grown oocytes (Teixeira Filho et al., 2002; Gilchrist et al., 2008; Chen et al., 2009). BMP-15 and GDF-9 play fundamental roles in regulating CC functions through the processes of mitosis, proliferation, apoptosis, luteinization, metabolism and expansion through mitogenic signaling transduction mechanisms (Erickson and Shimasaki, 2001; Teixeira Filho et al., 2002; van der Spuy and Dyer, 2004; Gilchrist et al., 2008; Chen et al., 2009). Data from in vitro models demonstrate that co-incubation of COC with either BMP-15 or GDF-9 substantially promotes oocyte maturation and enhances blastocyst production, as well as increases the total number of cells in the trophectoderm (Hussein et al., 2006) and inner cell mass of mouse embryos (Yeo et al., 2008). Following embryo transfer in mice, the rate of fetal survival almost doubles after exposure to BMP-15 or GDF-9, but no differences could be detected in implantation rates (Yeo et al., 2008). Importantly, both GDF-9 and BMP-15 are required for folliculogenesis in humans and their abnormal expression may be related to female infertility (Juegel et al., 2002; Teixeira Filho et al., 2002; Shimasaki et al., 2004; Artini et al., 2007; Wu et al., 2007a, b; Gilchrist et al., 2008), including increased correlations with PCOS pathologies (Francis et al., 2002; Teixeira Filho et al., 2002; van der Spuy and Dyer, 2004; Ciepiela et al., 2007; Dumesic et al., 2007b, Dumesic and Abbott, 2008; Gilchrist et al., 2008; Zhao et al., 2010). In infertile women, elevated FF BMP-15 levels are positively correlated with improved oocyte quality and higher rates of fertilization and embryonic development, suggesting that BMP-15 may be a good indicator of oocyte maturity and fertilization ability (Wu et al., 2007a, b). A recent study demonstrates that the expression of GDF-9 and BMP-15 tended to be higher in PCOS patients when compared with a control group, and thus may be involved in PCOS follicular dysplasia (Zhao et al., 2010). GDF-9 expression in CCs is lower in PCOS patients, which may lead to premature luteinization and decreased oocyte developmental competence and luteal generation (Takebayashi et al., 2000; Artini et al., 2007): this may also be correlated to elevated miscarriage rates in women with PCOS (Zhao et al., 2010). Therefore, the expression of BMP-15 and GDF-9 in both oocytes and CCs may provide valuable support for the ability to regulate the follicular microenvironment during the oocyte maturation process. Further study on the role of BMP-15 or GDF-9 during follicle growth and oocyte meiotic maturation will have important implications in understanding those factors that regulate the mechanisms behind the pathogenesis of PCOS, and help to improve IVM methods for oocytes from women with PCOS.

**Vascular endothelial growth factor family**

Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein belonging to the VEGF/platelet-derived growth factor family (Artini et al., 2007). In the ovary, VEGF is expressed in GCs and theca cells, but rarely in stroma cells (Artini et al., 2007) and is also present in the FF (Artini et al., 1998; Van Blerkom, 2000; Stouffer et al., 2001; Ocal et al., 2004). VEGF exerts its actions by binding to one of three receptors, VEGFR-1/Fit-1, VEGFR-2/KDR/Flk-1 or VEGFR-3/Fit-4, functioning via the signal transduction system (De Vries et al., 1992; Terman et al., 1992; Artini et al., 2007, 2009). VEGF plays an important role in angiogenesis, follicular vascularization and intrafollicular oxygenation, consequently impacting follicular maturation, oocyte quality, fertilization and embryo developmental competence (Itskovitz et al., 1991; Van Blerkom et al., 1997; Agrawal et al.,...
functions in follicular maturation and subsequent embryonic development (Luo et al., 2000; Bokal et al., 2005). In vitro culture studies show that VEGF stimulates the maturation of bovine oocytes during IVM, resulting in increased rates of fertilization and embryonic development (Luo et al., 2002; Bokal et al., 2005). In the ovary, the action of cytokines may be autocrine or paracrine, but soluble Fas (sFas) and sFas ligand (sFasL) (TNF family; sFas and sFasL proteins exert anti- and pro-apoptotic functions, respectively. The binding of sFasL with its receptor induces apoptosis, whereas sFas, acting as a functional antagonist, binds with sFasL to inhibit sFasL-mediated apoptosis by preventing death signal transduction (Ueno et al., 1999; Onalan et al., 2005). sFas can be detected in human sera, oviduct fluid and FF (Srivastava et al., 1998; van der Spuy and Dyer, 2004; Artini et al., 2006, 2007). In women with PCOS, elevated FF VEGF is closely associated with the development of ovarian hyperstimulation syndrome (Agrawal et al., 1998, 2002; Artini et al., 1998; Franks et al., 2002). Furthermore, it is well known that increased FF VEGF levels in PCOS patients is indicative of immature oocytes and poor fertilization rates (Artini et al., 2006, 2009).

An opposing study concluded that follicles containing higher FF VEGF concentrations provide better MI oocytes, compared with those with lower FF VEGF concentrations (Bokal et al., 2004). Among PCOS groups, reports suggest that prolonged hCG action results in elevated FF VEGF, consequently increasing the number of high-quality oocytes and embryos, as well as improving fertilization rates (Bokal et al., 2005): the same researchers also demonstrated that decreases in FF VEGF and E2 levels in PCOS women following GnRH antagonist administration have detrimental effects on follicular development, as compared with those women who were given agonists, consequently reducing oocyte and embryo quality (Bokal et al., 2009). Therefore, FF VEGF may serve as a dynamic indicator for the evaluation of follicular maturity, subsequently predicting oocyte maturity, fertilization success and embryo development in PCOS patients (Bokal et al., 2005, 2009); however, further research is required to uncover the true relationship between VEGF levels and subsequent success in PCOS women.

### Cytokine family

Cytokines encompass a large family of soluble polypeptide regulators that are produced widely throughout the body by cells of diverse embryological origin; the family comprises the interleukins (ILs ~ 35), leukemia inhibitory factor, tumor necrosis factor (TNF)α, soluble Fas (sFas) and sFas ligand (sFasL) (TNF subfamily). Within the ovary, the action of cytokines may be autocrine or paracrine, but not endocrine; they exist in the FF, suggesting their production by GCs (Buyalos et al., 1992; Zolti et al., 1992; Jasper and Norman, 1995; Amato et al., 2003; Gallinelli et al., 2003), and have regulatory functions in follicular maturation and subsequent embryonic development (Coskun et al., 1998; Hsieh et al., 2005). In PCOS patients cytokines are believed to play a role in ovarian hyperstimulation (Pellicer et al., 1999) and hyperandrogenism (Escobar-Morreale et al., 2001); however, these reports have been disputed (Gonzalez et al., 1999; Deshpande et al., 2000; Amato et al., 2003).

### Interleukins

ILs are a group of cytokines (secreted proteins/signaling molecules) that are expressed by leukocytes (Wu et al., 2007a, b). Studies have elucidated that ILs, namely IL-1, IL-2, IL-6, IL-8, IL-11, IL-12 and other cytokines, play multiple roles in folliculogenesis, ovulation and corpus luteum function (Barak et al., 1992; Naz and Butler, 1996; Branisteau et al., 1997; Gallinelli et al., 2003). FF IL-12 levels vary within immature and pre-ovulatory follicles (Coskun et al., 1998); the presence of FF IL-12 has been associated with fertilization failure (Gazvani et al., 2000). An important study has demonstrated that decreased FF IL-12 level and increased FF IL-13 level in PCOS patients is correlated with a reduced rate of oocyte maturation, fertilization and pregnancy, but this reduction did not reach statistical significance (Gallinelli et al., 2003).

### Tumor necrosis factorα

TNFα is a multifunctional hormone-like polypeptide, which is involved in a wide range of physiological roles in regulating ovarian function, exerting an influence on proliferation, differentiation, follicular maturation, steroidogenesis and apoptosis (Lédée-Bataille et al., 2001; van der Spuy and Dyer, 2004; Artini et al., 2007). In the ovary, TNFα is expressed by the oocyte, theca cells, GCs and corpora lutea (Artini et al., 2007). One IVM model, coupling porcine oocyte co-incubation with high levels of TNFα, reported decreased oocyte maturation and increased proportions of oocytes with abnormal chromosomal alignment and cytoskeleton structure (Ma et al., 2010). Alterations in FF TNFα levels are correlated with poor-quality oocytes in women undergoing IVF (Cianci et al., 1996; Carlb erg et al., 2000; Lee et al., 2000), resulting in reduced rates of fertilization, embryonic development and pregnancy outcome (Ma et al., 2010). Furthermore, increased levels of FF TNFα in women with PCOS are significantly and inversely correlated to FF E2 levels, which is again indicative of poor-quality oocytes and embryos (Gallinelli et al., 2003; Amato et al., 2003; Wu et al., 2007a, b; Kim et al., 2009).

### Soluble Fas and sFas ligand

sFas and sFasL are transmembrane proteins belonging to the TNF subfamily; sFas and sFasL proteins exert anti- and pro-apoptotic functions, respectively. The binding of sFasL with its receptor induces apoptosis, whereas sFas, acting as a functional antagonist, binds with sFasL to inhibit sFasL-mediated apoptosis by preventing death signal transduction (Ueno et al., 1999; Onalan et al., 2005). sFas can be detected in human sera, oviduct fluid and FF (Srivastava et al., 1998; van der Spuy and Dyer, 2004) and sFas levels in the FF are positively correlated to oocyte maturity and survival in IVF patients (Sarandakou et al., 2003). Some studies have demonstrated that the sFas—sFasL system involves apoptosis of theca cells and GCs in PCOS patients (Cataldo et al., 2000; Webber et al., 2003; Onalan et al., 2005). Furthermore, these reports suggest that reduced serum levels of sFas and DNA fragmentation in luteinized GC are found in women with PCOS undergoing IVF treatment. Patients with PCOS who are treated with metformin display anti-apoptotic effects owing to elevated serum sFas levels and reduced FF sFasL levels; GC DNA fragmentation was also reduced, thus increasing implantation and clinical pregnancy rates (Onalan et al., 2005). According to these data, one may speculate that abnormalities in the sFas—sFasL system are indicative of PCOS pathogenesis, further associating decreased oocyte quality, lower fertilization rates and higher miscarriage rates with PCOS.
Other microenvironment factors

Homocysteine
Homocysteine (Hcy) is a homologue of the amino acid cysteine, differing by an additional methylene group, and can be recycled into methionine or converted into cysteine in the presence of B-vitamins. Many studies have established that elevated Hcy levels in serum and FF are inversely associated with oocyte and embryo quality (Steegers-Theunissen et al., 1992; Ebisch et al., 2006; Berker et al., 2009; Nafiye et al., 2010), resulting in decreased fertilization and pregnancy rates, and increased miscarriage rates in PCOS patients undergoing IVF treatment (Ludwig et al., 1999; Plachot et al., 2003; Yarali et al., 2001; Loverro et al., 2002; Schacter et al., 2003; Heijnen et al., 2006; Kaya et al., 2009; Berker et al., 2009; Nafiye et al., 2010). Previous studies demonstrated that IVF patients who have higher E2 levels in FF have improved rates of oocyte fertilization, cleavage and implantation (Botero-Ruiz et al., 1984; Foong et al., 2005; Berker et al., 2009). Furthermore, elevated levels of Hcy in FF and serum may suppress E2 synthesis, and consequently interfere with ovarian follicular developmental competence, oocyte maturation and fertilization in women with PCOS (Boxmeer et al., 2008; Berker et al., 2009). Therefore, all of these results suggest that high levels of FF Hcy have a detrimental effect on oocyte and embryo quality, and may serve as a useful indicator for potential success in PCOS patients undergoing assisted reproduction.

Leptin
Leptin is a 16 kDa protein hormone that plays a key role in regulating energy intake, energy expenditure and a balance between the two. It has also served as a biomarker for body fat. In the field of assisted reproduction, leptin has been used to predict oocyte maturity and embryo quality (Barroso et al., 1999; Georgios et al., 2005). High leptin levels in the FF and serum are closely associated with decreased oocyte maturity, poor fertilization and embryo quality, and lower pregnancy rates in PCOS patients (Mantzoros et al., 2000; Georgios et al., 2005; Li et al., 2007). Some studies show that elevated leptin levels in women with PCOS play an important role in the pathogenesis of PCOS (Scarpace et al., 2000; Pasquali et al., 2006; Cervero et al., 2006; Li et al., 2007). Others suggest that elevated leptin levels in the ovary may block E2 production, disturbing follicular development and oocyte maturation (Mantzoros et al., 2000). Hyperleptinemia, or increased FF leptin, in PCOS patients may impair embryo quality and pregnancy rates (Anifandis et al., 2005; De Placido et al., 2006; Li et al., 2007). In contrast, other investigations have shown that FF leptin is decreased in women with PCOS and is not a useful marker for oocyte quality, fertilization or embryo development (Welt et al., 2003; Plati et al., 2009). Hence, the involvement of leptin and its significance in the establishment of PCOS pathophysiology, especially its impact on oocyte maturation competence, needs further clarification.

FF meiosis-activating sterol
FF meiosis-activating sterol (FF-MAS) is an endogenous signaling molecule and an intermediate in the cholesterol biosynthetic pathway, which is present in FF (Byskov et al., 1999, 2002; Bokal et al., 2006; Grondahl, 2008). Many IVM studies demonstrate that exposure to FF-MAS can promote nuclear and cytoplasmic maturation of the oocyte (Tsafiri and Motola, 2007) and improved fertilization and early embryonic development in humans and other mammals (Cukurocam et al., 2003; Bvens et al., 2004; Faerge et al., 2006; Grondahl, 2008). Interestingly, reports show that FF-MAS enhances successful IVM of oocytes retrieved from women with PCOS (Chian et al., 2005; Grondahl, 2008). Furthermore, a leading report suggests that the concentrations of FF-MAS significantly increase during the periovulatory period, between 10–14 and 34–38 h after hCG administration; this may be related to increased numbers of MII stage oocytes retrieved from PCOS patients (Bokal et al., 2006). This knowledge may prove to be useful in the implementation of IVM protocols for PCOS patients.

Immunoreactive corticotrophin-releasing hormone, tissue inhibitor of metalloproteinase-1 & 2 and visfatin
Immunoreactive corticotrophin-releasing hormone (IrCRH) is a 41-amino acid neuropeptide (Vales et al., 1981), synthesized by theca cells and/or the mature oocyte itself (Mastorakos et al., 1993, 1994). Study has found that decreased FF IrCRH levels are correlated with oocyte dysfunction in women with PCOS (Mastorakos et al., 1994). Other reports suggest that FF tissue inhibitor of metalloproteinase (TIMP)-1 & 2 levels are significantly lower in women with PCOS than in NOW (Lahav-Bratz et al., 2003). In contrast, there was no difference in basal production of TIMP-1 by cells in culture between women with PCOS and NOW; however, matrix metalloproteinases-2 and 9 are significantly increased in the FF of women with PCOS (Shalev et al., 2001), suggesting an association with inappropriate atresia. In a recent study, serum visfatin levels were significantly increased in women with PCOS, whereas FF visfatin levels do not differ when compared with non-PCOS patients (Plati et al., 2009). On the basis of these studies, it is difficult to assign specific effects to these factors, although their association to physiological or pathological functions in PCOS is evident.

Renin
Renin (also known as angiotensinogenase) participates in the body’s renin—angiotensin system. It is known that ovarian renin has an impact on the developmental and fertilization competence of human oocytes (Itskovitz et al., 1991; Van Blerkom et al., 1997; Loret de Mola et al., 1999; Bokal et al., 2005). Investigations suggest that decreased FF renin is related to increased rates of oocyte maturation and fertilization, and better subsequent embryo quality (Bokal et al., 2003, 2004, 2005).

Resistin
Resistin is a 12.5 kDa cysteine-rich protein hormone, synthesized by adipose tissues (Seow et al., 2005). Recent studies demonstrate that there are no significant differences in either serum or FF resistin concentrations between PCOS patients and controls; these are also not significantly correlated with fertilization rates, implantation rates, clinical pregnancy rates or early miscarriage rates in PCOS patients (Seow et al., 2005). These data indicate that resistin is unlikely to be a useful biomarker for oocyte developmental competence during IVF treatment in PCOS women.

Oxidative stress
Reactive oxygen species (ROS) are involved in many physiological functions and act as mediators in a variety of signaling pathways.
Damage to biological systems caused by an excess of ROS is referred to as OS (Gupta et al., 2009). In women with PCOS, data show that increased FR ROS and decreased total antioxidant capacity and superoxide dismutase are closely associated with lower rates of oocyte maturation and fertilization, poor embryo quality and decreased pregnancy rates (Sabatini et al., 2000; Ruder et al., 2008; Bausenwein et al., 2010; Chattopadhayay et al., 2010). ROS degrade polyunsaturated lipids, forming malondialdehyde (MDA) (Pryor and Stanley, 1975). Elevated FF MDA levels are directly correlated with increased numbers of immature oocytes retrieved, lower rates of fertilization and embryonic development, and consequently, lower pregnancy rates in PCOS patients (Yildirim et al., 2007; Berker et al., 2009). Therefore, ROS may impair oocyte quality via alterations in the balance of FFFs in the follicular microenvironment.

Concluding remarks

Patients with PCOS are typically characterized by production of an increased numbers of oocytes during stimulation in an IVF cycle; however, these women suffer from poor-quality oocytes and embryos, lower fertilization, cleavage and implantation rates, and higher miscarriage rates. A series of extra- and intra-ovarian factors causing abnormalities during folliculogenesis, follicular growth and oocyte meiotic maturation processes have been identified. Whether these abnormalities have a direct influence on GC–oocyte interactions and oocyte meiotic maturation, fertilization, embryonic development and pregnancy, or whether the influences are through circulating endocrine and local paracrine/autocrine mechanisms, requires further clarification. Although many studies have been performed in all aspects of endocrinology, genetics, metabolism and reproduction in the etiology and pathology of PCOS, it remains a challenge for clinical and academic scientists alike to elucidate the molecular mechanisms involved; in particular, the oocyte’s developmental competence and genetic disruption are undoubtedly important considerations. Therefore, systematic screening for key intra-ovarian factors which are related to PCOS (such as AMH, Hcy, growth factors and cytokines) coupled with proper treatment for each PCOS phenotype are essential issues in achieving success for PCOS patients undergoing assisted reproduction, in an effort to effectively improve oocyte maturation and developmental competence.

Authors’ roles

J.Q. is responsible for data collection and outline design; H.L.F. is responsible for manuscript preparation.

Acknowledgements

We would like to thank Gerald Scholl, M.D. and Mr Dennis Marchesi for their critical review and comments during the preparation of this manuscript.

Funding

This work is partially supported by grants from National Outstanding Young Scientist Grant, China (# 30825038) (Q.J); and Academic Research Project (GRTR-156) from Ferring Pharmaceuticals, NJ, USA (H.L.F).

References

Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, Morris DV, Price J, Jacobs HS. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;ii:1375–1379.

Adashi EY. Intraovarian regulation: the proposed role of insulin-like growth factors. New York Acad Sci 1993;687:10–13.

Agrawal R, Conway G, Sladkevicius P, Tan SL, Engmann L, Payne N, Bekir J, Campbell S, Jacobs H. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 1998;70:651–658.

Agrawal R, Jacobs H, Payne N, Conway G. Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril 2002;78:1164–1169.

Almahbobi G, Trounson AO. The role of intraovarian regulators in the etiology of the polycystic ovarian syndrome. Reprod Med Rev 1996;5:151–168.

Almahbobi G, Misajon A, Hutchinson P, Lolatgis N, Trounson AO. Hypexpression of epidermal growth factor receptors in granulosa cells from women with polycystic ovary syndrome. Fertil Steril 1998;70:750–758.

Amato G, Lizzo A, Tucker AT, Bellastella A. Lack of insulin-like growth factor binding protein-3 variation after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome undergoing in vitro fertilization. Fertil Steril 1999;72:454–457.

Amato G, Conte M, Mazzotti G, Lalli E, Vitolo G, Tucker AT, Bellastella A, Carella C, Lizzo A. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003;101:1177–1182.

Anderson C, Trounson AO. The effect of testosterone on the maturation and developmental capacity of murine oocytes in vitro. Hum Reprod 1995;10:2377–2381.

Anderson RA, Groome NP, Baird DT. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono- ovulation. Clinical Endocrinol 1998;48:577–684.

Andreani CL, Piroir E, Lazzarini N, Lanzone A, Caruso A, Mancuso S. Effect of follicular fluid on granulosa luteal cells from polycystic ovary syndrome. Fertil Steril 1996;61:2107–2113.

Anifandis G, Knoulstini E, Stefanidis I, Liakopoulos V, Leivaditis C, Mantzavinos T, Vamvakopulos N. Serum and FF leptin levels are correlated with human embryo quality. Reproduction 2005;130:917–921.

Artini PG, Battaglia CD, Ambrogio G, Barrea C, Droghini F, Volpe A, Genazzani AR. Relationship between human oocyte maturity, fertilization and follicular fluid growth factors. Hum Reprod 1996;11:2107–2113.

Artini PG, Battaglia CD, Ambrogio G, Barrea C, Droghini F, Volpe A, Genazzani AR. Correlation between the amount of follicle stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations in women undergoing in vitro fertilization. Gynecol Endocrinol 1998;12:243–247.

Artini PG, Monteleone P, Toldin MR, Matteucci C, Ruggiero M, Cela V, Genazzani AR. Growth factors and folliculogenesis in polycystic ovary patients. Expert Rev Endocrinol Metab 2007;2:215–223.

Artini PG, Monti M, Matteucci C, Valentin V, Cristello F, Genazzani AR. Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol 2006;22:465–470.

Artini PG, Ruggiero M, Parisen Toldin MR, Monteleone P, Monti M, Cela V, Genazzani AR. Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Hum Fertil 2009;12:40–44.

Ashkenazi H, Cao X, Motola S, Popliker M, Conti M, Tsafiri A. Epidermal growth factor family members: endogenous mediators of the ovariolytic response. Endocrinology 2005;146:77–84.

Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovarian syndrome in...
Coskun S, Uzmucu M, Jaroudi K, Hollander JM, Parhar RS, al-Sedairy ST. Presence of leukemia inhibitory factor and interleukin-12 in human follicular fluid during follicular growth. Am J Reprod Immunol 1998;40:13–18.

Craig LB, Ke RW, Kutheth WH. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002;78:487–490.

Cukurcam S, Heggale-Hartung C, Eichenlaub-Ritter U. Meiosis activating sterol protects oocytes from precocious chromosome segregation. Hum Reprod 2003;18:1908–1917.

Da Silva SJ, Gardner JO, Taylor JE, Springbett A, De Sousa PA, Anderson RA. Brain-derived neurotrophic factor promotes bovine oocyte cytoplasmic competence for embryo development. Reproduction 2005;129:423–434.

Das K, Phipps WR, Hensleigh HC, Tagatz GE. Epidermal growth factor in human follicular fluid stimulates mouse oocyte maturation in vitro. Fertil Steril 1992;57:695–901.

Das M, Gillott DJ, Saridano E, Dijahanbakho O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated oocytes in women with polycystic ovary syndrome. Hum Reprod 2008;23:2112–2126.

De La Fuente R. Chromatin modifications in the germinal vesicle (GV) of mammalian oocytes. Dev Biol 2006;292:1–12.

De La Fuente R, O’Brien MJ, Eppig JJ. Epidermal growth factor enhances in vitro developmental competence of maturing mouse oocytes. Hum Reprod 1999;14:3060–3068.

De Placido G, Alviggi C, Clarizia R, Mollia A, Alviggi E, Strina L, Fiore E. Intra-follicular leptin concentration as a predictive factor for in vitro oocyte fertilization in assisted reproductive techniques. J Endocrinol Invest 2006;29:719–726.

De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:969–991.

Desforges-Bullet V, Gallo C, Lefebvre C, Pigpy N, Dewally D, Jonard CJ. Increased antimullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril 2010;94:198–204.

Deshpande RR, Chang MY, Chapman JC, Micheal SD. Alteration of cytokine production in follicular cystic ovaries induced in mice by neonatal estradiol injection. Am J Reprod Immunol 2000;44:80–88.

Di Clemente N, Josso N, Gouedard L, Belville C. Components of the anti-Mullerian hormone signaling pathway in gonads. Mol Cell Endocrinol 2003;211:9–14.

Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008;10:e31–e62.

Diamanti-Kandarakis E, Katsikis I, Pippi C, Kandarakis E, Poulka A, Papavassiliou AG, Panidis D. Increased serum advanced glycation end-products is a distinct finding in androgenized female rhesus monkeys undergoing gonadotropin stimulation for in vitro fertilization. J Endocrinol Invest 2008;31:634–641.

Dissen GA, Garcia-Rudaz C, Paredes A, Mayer C, Mayerhofer A, Ojeda SR. Excessive ovarian production of Nerve Growth Factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinol 2009;150:2906–2914.

Dragic K, Liu HC, He ZY, Witkin S, Rosenwaks Z, Spandorfer S. Association of anti-mullerian hormone and decreased FSH levels in follicular fluid obtained in women with a history of recurrent pregnancy loss. Fertil Steril 2000;73:395–405.

Dzik A, Lambert-Messerlian G, Itso VM, Soares JB, Pinotti JA, Seifer DB. Inhibin B response to EFORF is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. Fertil Steril 2000;74:1114–1117.

Ebisch IWM, Peters WH, Thomas CM, Wetzel AM, Peer PG, Steegers-Theunissen RP. Hormocysteine, glutathione and related thiol affects fertility parameters in the (sub) fertile couple. Hum Reprod 2006;21:1725–1733.

Ebner T, Sommergruber M, Moser M, Sheibl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21:2022–2026.

Eden JA, Jones J, Carter GD, Alaghband-Zadeh J. A comparison of follicular fluid levels of insulin-like growth factor-I in normal dominant and cohort follicles, polycystic and multicystic ovaries. Clin Endocrinol (Oxf) 1988;29:327–336.

Eden JA, Jones J, Carter GD, Alaghband-Zadeh J. Follicular fluid concentrations of insulin-like growth factor 1, epidermal growth factor, transforming growth factor-alpha and sex-steroids in volume matched normal and polycystic human follicles. Clin Endocrinol 1990;32:395–405.

Eladar-Geva T, Spitz I, Groome NP, Margalioth EJ, Homburg R. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Hum Reprod 2001;16:2552–2556.

Eppig JJ, O’Brien MJ, Pendola FL, Watanabe S. Factors affecting the developmental competence of mouse oocytes grown in vitro: follicle stimulating hormone and insulin. Biol Reprod 1990;59:1445–1453.

Erickson GF, Shimazaki S. The physiology of folliculogenesis: the role of novel growth factors. Fertil Steril 2001;76:943–949.

Erickson GF, Chung DG, Sit A, DePaolo LV, Shimazaki S, Ling N. Follistatin concentrations in follicular fluid of normal and polycystic ovaries. Human Reprod 1995;10:2120–2124.

Escobar-Morreale HF, Calvo RM, Sancho J, San Millan JL. TNF-α and hyperandrogenism: A clinical, biochemical, and molecular genetic study. J Clin Endocrinol Metab 2001;86:3761–3767.

Faenger I, Strejcek F, Laurinck J, Rath D, Niemann H, Schellander K, Rosenkranz C, Hyttel PM, Grøndahl C. The effect of FF-MAS on porcine cumulus–oocyte complex maturation, fertilization and pronuclear formation in vitro. Zygote 2006;14:189–199.

Fallat ME, Cook C, Sow Y, Carrillo A, Marra M. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 1997;67:962–965.

Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R, Tazeb J. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007;92:1796–1802.

Findlay JK. An update on the roles of inhibin, activin and follistatin as local regulators of folliculogenesis. Biol Reprod 1993;48:15–23.

Foong SC, Abbott DH, Lesnick TG, Session DR, Walker DL, Dumesic DA. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone. Fertil Steril 2005;83:1377–1383.

Franchimont P, Hazout A, Menezo Y, Colette J. Insulin-like growth factors I and II in follicular fluid and serum concentrations of interleukin-12 and interleukin-8 in IVF cycles. Fertil Steril 1999;71:943–949.

Frisch SO, Elsworth DJ, Kueblbeck T, Winnefeld A, Siewers AE, Klein H. Association of inhibin-A, inhibin-B, and follistatin in human follicular fluid with developmental competence of mouse oocytes. Hum Reprod 2005;20:1365–1372.

Frydman R, Taieb J. Anti-Müllerian hormone concentrations in the follicular fluid of women with polycystic ovaries. Mol Hum Reprod 2003;9(Suppl.):S456.

Gazvani MR, Bates M, Vince G, Christmas S, Lewis-Jones DI, Kingsland C. Follicular fluid concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic ovary syndrome. Fertil Steril 2002;79:1365–1372.

Gazvani MR, Bates M, Vince G, Christmas S, Lewis-Jones DI, Kingsland C. Follicular fluid concentrations of interleukin-12 and interleukin-8 in IVF cycles. Fertil Steril 2000;74:953–958.
Gonzalez E, Eleni K, Ioannis S, Vassilios L, Constantinos L, Themis M, Nikolaos V. Serum and follicular fluid leptin levels are correlated with human embryo quality. Reproduction 2005;130:917–921.

Gianaroli L, Magli MC, Ferrari AP, Fortini D, Grieco N. Pronuclear morphology and chromosomal abnormalities as scoring criteria for embryo selection. Fertil Steril 2003;80:341–349.

Gianaroli L, Magli MC, Ferrari AP, Lippi M, Borghi E, Emrini B. Oocyte euploidy, pronuclear zygote morphology and embryo chromosomal complement. Hum Reprod 2007;22:241–249.

Gilchrist RB, Lane M, Thompson JG. Oocyte-secreted factors: regulators of cumulus cell function and oocyte quality function and oocyte quality. Hum Reprod Update 2008;14:159–177.

Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:46–52.

Goff A, Yang Z, Cortvindt R, Smits J, Miron P. Protein synthesis during maturation of bovine oocytes, effect of epidermal growth factor. Reprod Domest Anim 2001;36:19–24.

Gonzalez E, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999;48:347–441.

Goud PT, Goud AP, Qian C, Laverge H, Van der Elst J, De Sutter P, Dhont M. In vitro maturation of bovine oocytes, effect of epidermal growth factor. Dan Med Bull 2008;55:1–16.

Gupta S, Malhotra N, Sharma D, Chandra A, Ashok A. Oxidative stress and its role in female infertility and assisted reproduction: Clinical implications. Int J Fertil Steril 2009;2:147–164.

Hamilton-Fairley D, Kidd Y, Watson H, Paterson C, Franks S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol 1999;106:128–131.

Hammed ME, Fischer-Hammed C, Hoffmeister H, Huebner N, George T, Latinkle RA, Mihalovska MM, Weber R, George T, Ismail MA. Exposure to diethylstilbestrol at high doses increases the risk of late pregnancy loss in women with polycystic ovaries. J Reprod Med 2008;53:46–52.

Hofmann GE, Scott RT Jr, Brzyski RG, Jones HW Jr. Immunoreactive epidermal growth factor concentrations in follicular fluid obtained from new and repeated cycles of normal women of advanced reproductive age. Fertil Steril 1998;70:125–1231.

Hofmann GE, Scott RT Jr, Brysly RG, Jones HW Jr. Immunoreactive epidermal growth factor concentration in follicular fluid obtained from in vitro fertilization. Fertil Steril 1990;54:303–307.

Hornburg R, Jacobs HS. Etiology of miscarriage in polycystic ovary syndrome. Fertil Steril 1989;51:196–198.

Hsieh YY, Chang CC, Tsai HD, Lin CS. Leukemia inhibitory factor in follicular fluid is not related to the number and quality of embryos as well as implantation and pregnancy rates. Biochem Genet 2005;43:501–506.

Hsieh M, Zamah AM, Conti M. Epidermal Growth Factor-Like Growth Factors in the Reproductive System: An Overview. Endocr Rev 2002;23:100–148.

Hsieh M, Zamah AM, Conti M. Epidermal Growth Factor-Like Growth Factors in the Reproductive System: An Overview. Endocr Rev 2002;23:100–148.

Hsieh M, Zamah AM, Conti M. Epidermal Growth Factor-Like Growth Factors in the Reproductive System: An Overview. Endocr Rev 2002;23:100–148.
Lauffer N, DeCherney AH, Hasselton LP, Behrman HR. Steroid secretion by the human egg—corona—cumulus complex in culture. J Clin Endocrinol Metab 1984; 58:1153–1157.

Laven JS, Mulders AG, Thirumeni AP. Anti-Mullerian hormone (AMH) serum concentrations in normo-ovulatory and anovulatory women. J Clin Endocrinol Metab 2004;89:318–323.

Lédée-Bataille N, Delage GL, Taupin JL, Dubanchet S, Taieb J, Moreau JF, Chauvat G. Follicular fluid concentration of leukemia inhibitory factor is decreased among women with polycystic ovarian syndrome during assisted reproduction cycles. Hum Reprod 2000;16:2073–2078.

Lee KS, Joo BS, Na YJ, Yoon MS, Choi OH, Kim WW. Relationships between concentrations of tumor necrosis factor-α and nitric oxide in follicular fluid and oocyte quality. J Assis Reprod Genet 2000;17:222–228.

Legro RS. Polycystic ovarian syndrome: the new millennium. Mol Cell Endocrinol 2001;184:67–92.

Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Müllerian hormone (AMH) as a predictor of IVF outcome. Reprod BioMed Online 2007;14:602–610.

Ley-Santín MA, Moore GE, Winston RM, Hardy K. Routine addition of human insulin-like growth factor-I ligand could benefit clinical in-vitro fertilization culture. Fertil Steril 1998;70:4771–4776.

Lighten AD, Moore GE, Winston RM, Hardy K. Routine addition of human insulin-like growth factor-I ligand could benefit clinical in-vitro fertilization culture. Hum Reprod 1998;13:3144–3150.

Liu HC, He ZY, Mele CA, Veeck LL, Davis O, Rosenwaks Z. Human endometrial stromal cells improve embryo quality by enhancing the expression of insulin-like growth factor growth factors and their receptors in cocultured human preimplantation embryos. Fertil Steril 1999;71:361–367.

Lockwood GM, Mutukrishna S, Ledger WL. Inhibins and activins in human ovulation, conception and pregnancy. Hum Reprod Update 1998;4:284–295.

Loret de Mola JR, Goldfarb JM, Hecht BR, Babbo CJ, Friedlander MA. Anti-Müllerian hormone (AMH) as a predictor of IVF outcome. Hum Reprod 2000;15:1014–1020.

Lyalle Y, Sevtap K, Muammer D, Emre O, Senol E, Leyla M. The effect of serum and follicular intracellular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril 2010;93:1864–1869.

Magoffin DA, Jakimiuk AJ. Inhibin A, inhibin B and activin A concentrations in follicular fluid from women with polycystic ovary syndrome. Hum Reprod Update 2006;12:3144–3150.

Magoffin DA, Jakimiuk AJ. Inhibin A, inhibin B and activin A concentrations in follicular fluid from women with polycystic ovary syndrome. Hum Reprod 2000;15:539–544.

Marca AL, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stable G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2009;15:113–130.

Mashiach R, Amit A, Hassan J, Amzalag S, Almgov B, Yosef DB, Lessing JB, Limor R, Azem F. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome. Fertil Steril 2010;93:2299–2302.

Mastorakos G, Webster EL, Friedman TC, Chrousos GP. Immuno-reactive corticotrophin-releasing hormone and its binding sites in the rat ovary. J Clin Invest 1993;92:961–968.

Mastorakos G, Scopa CD, Vronidou A, Friedman TC, Kattis D, Phenekos C, Merino MJ, Chrousos GP. Presence of immunoreactive corticotrophin-releasing hormone in normal and polycystic human ovaries. J Clin Endocrinol Metab 1994;79:1191–1197.

Mori L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009;15:477–488.

Mulders AG, Laven JS, Imani B, Eijkemans MJ, Fauser BC. IVF outcome in anovulatory infertility (WHO group 2)—including polycystic ovary syndrome following previous unsuccessful ovulation induction. Reprod Biomed Online 2003;7:50–58.

Munne S, Dailey T, Sultan KM, Grifo J, Cohen J. The use of first polar bodies for preimplantation diagnosis of aneuploidy. Hum Reprod 1995;10:1014–1020.

Nafie Y, Sevtap K, Muammer D, Emre O, Senol E, Leyla M. The effect of serum and follicular intracellular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril 2010;93:1864–1869.

Navarro PA, Barcelos ID, Viera RC, Ferreira EM, Reis RM, Ferriani RA. Evaluation meiotic spindle and chromosome configuration of in vitro matured human oocytes from PCOS and endometriotic patients submitted to ovariain stimulation: Preliminary results. Fertil Steril 2007;88(Suppl.):S297.

Navarro PA, Barcelos ID, Ferreira EM, Gorgenon RC, Araujo MC, Viera RC. Comparative analysis of the spindle and chromosome configurations of in vitro-matured oocytes from patients with polycystic ovary syndrome and from controls: a pilot study. Fertil Steril 2009;92(Suppl.):S68.

Naze RK, Butler A. Interleukins-6 and -8 levels in sera and cervical mucus of fertile, idiopathic infertile, and immuno-infertile women: implication in infertility. Am J Reprod Immunol 1996;35:534–540.

Nelson VL, Qin K, Rosenfeld RL, Wood JR, Penning TM, Legro RS, Strauss JF 3rd, McAllister JM. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925–5933.

Nichols SM, Gerbolini L, Gonzalez-Martinez JA, Bavister BD. Effect of in vitro maturation and age on oocyte quality in the rhesus macaque Macaca mulatta. Fertil Steril 2010;93:1591–1600.

Norman RJ, Milner CR, Groome NP, Robertson DM. Circulating follistatin concentration are higher and active concentrations are lower in polycystic ovarian syndrome. Hum Reprod 2001;16:668–672.

Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2009;16:224–231.

Ocal P, Aydin S, Cepni I, Idil S, Idil M, Uzun H, Benian A. Follicular fluid concentrations of vascular endothelial growth factor, inhibin A and inhibin B in IVF cycles: are they markers for ovarian response and pregnancy outcome? Eur J Obstet Gynecol Reprod Biol 2004;115:194–199.

Oko MA, Laird SM, Tuckerman EM, Li TC. Serum androgens level in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998;69:682–690.

Onalan G, Selam B, Baran Y, Cinick M, Onalan R, Gundüz U, Ural AU, Pabuccu R. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. Hum Reprod 2005;20:2391–2395.

Onalan G, Selam B, Onalan C, Ceyhan T, Cinick M, Pabuccu R. Serum and follicular fluid levels of soluble Fas and soluble Fas ligand in IVF cycles. Eur J Obstet Gynecol Reprod Biol 2006;125:85–91.

Oosterhuis GJ, Vermes I, Lambalk CB, Michgelsen HW, Schoemaker J. Insulin-like growth factor (IGF-I) and IGF binding protein-3 concentrations in fluid from human stimulated follicles. Hum Reprod 1998;13:285–289.

Ozolins PM, Beifeld P, Krussel JS, Hirchenhain J, Jeyendran RS, Koldovsky U. Epididymal growth factor and leukemia inhibitory factor levels in follicular fluid. J Endocrinol Invest 1999;22:951–955.

Padhy N, Sathya ML, Varma TR. Antral follicle size in the down regulated cycle and is related to in vitro fertilization outcome. J Hum Reprod Sci 2009;2:68–71.
Tao Z, Yan L. Luteinizing hormone and insulin inducing earlier and excess expression of luteinizing hormone receptor messenger ribonucleic acids in granulosa cells of polycystic ovarian syndrome. Fertil Steril 2005;84(Suppl.):S426–S427.

Tarlatzis BC, Grimbizis G. The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization. J Assist Reprod Genet 1997;14:1–4.

Teissier MP, Chable H, Paulhac S, Aubard Y. Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: relationship between steroid concentrations, follicle size, oocyte quality and fecundability. Hum Reprod 2000;15:2471–2477.

Teixeira Filho FL, Barata EC, Lee TH, Suh CS, Matsui M, Chang RJ, Shimasaki S, Ericsson GF. Ablation of growth factor differentiation factor-9 in oocytes of women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;87:1337–1344.

Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992;187:1579–1586.

Tesarik J, Mendoza C. Nongenomic effects of 17 beta-estradiol on maturing human oocytes: relationship to oocyte developmental potential. J Clin Endocrinol Metab 1995;80:1438–1443.

Tesarik J, Mendoza C. Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Hum Reprod Update 1997;3:95–100.

Tian L, Shen H, Lu Q, Norman RJ, Wang J. Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J Clin Endocrinol Metab 2007;92:1430–1433.

Toulis KA, Gouli DG, Farmakiotis D, Georgopoulou CS, Katsikis I. Diagnosis of polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009;15:297–307.

Tsafni A, Motola S. Are steroids dispensable for meiotic resumption in mammals? Trends Endocrinol Metab 2007;18:321–327.

Tse AC, Ge W. Differential regulation of betacellulin and heparin-binding EGF-like growth factor in cultured zebrafish ovarian follicle cells by EGF family ligands. Comp Biochem Physiol A Mol Integr Physiol 2009;153:13–17.

Tuckerman EM, Okon MA, Li T, Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril 2000;74:771–779.

Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999;5:3529–3533.

Urman B, Tiras B, Yakin K. Assisted reproduction in the treatment of polycystic ovarian syndrome. Reprod Biomed Online 2004;8:419–430.

Vales W, Spiess J, River J. Characterization of 41-residue ovine hypothalamic peptide that stimulates secretion of corticotrophin and b-endorphin. Science 1981;213:1394–1397.

Van Blerkom J, Antczak M, Schrader R. The developmental potential of the human oocyte and subsequent embryonic development. Hum Reprod 1999;14:257–260.

Wang YT, Tang L, Cai J, Lu XE, Xu J, Zhu XM, Luo Q, Huang HF. High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development. Hum Reprod 2007b;22:1526–1531.

Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, Franks S. Formation and early development of follicles in the polycystic ovary. Lancet 2003;362:1017–1021.

Weenen C, Laven J, Von Bergh A, Cranfield M, Groome N, Visser J, Kramer P, Fauser B, Themmen A. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77–83.

Weghofer A, Munne S, Chen S, Barad D, Gleicher N. Lack of association between polycystic ovary syndrome and embryonic aneuploidy. Fertil Steril 2007;88:900–905.

Welt CK, Schneyer AL, Heist K, Manterza CS. Leptin and soluble leptin receptor in follicular fluid. J Assist Reprod Genet 2003;20:495–501.

Welt CK, Taylor AE, Fox J, Messerlian GM, Adams JM, Schneyer AL. Follicular Arrest in Polycystic Ovary Syndrome Is Associated with Deficient Inhibin A and B Biosynthesis. J Clin Endocrinol Metab 2005;90:5582–5587.

Wen XS, Tozer AJ, Butler SA, Bell CM, Docherty SM, Iles RK. Follicular fluid levels of inhibin A, inhibin B, and activin A levels reflect changes in follicle size but are not independent markers of the oocyte’s ability to fertilize. Fertil Steril 2006;85:1723–1729.

Westergaard LG, Andersen CY. Epidermal growth factor (EGF) in human preovulatory follicles. Hum Reprod 1989;4:257–260.

Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 2002;57:343–350.

Wood JR, Dumesci DA, Abbott DH, Strauss JF III. Molecular abnormalities in oocytes with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab 2007;92:705–713.

Wu R, Fuji S, Ryan NK, Van der Hoek KH, Jasper MJ, Sini I, Robertson SA, Robker RL, Norman RJ. Ovarian leukocyte distribution and cytokine/chemokine mRNA expression in follicular fluid cells in women with polycystic ovary syndrome. Hum Reprod 2007a;22:527–535.

Wu YY, Tang L, Cai J, Lu XE, Xu J, Zhu XM, Luo Q, Huang HF. High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development. Hum Reprod 2007b;22:1526–1531.

Wynn P, Picton HM, Krappe JA, Rutherford AJ, Balen AH, Gosden RG. Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in vitro maturation. Hum Reprod 1998;13:3132–3138.

Yarali H, Yildirim A, Aybar F, Kabukci G, Bukuzmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511–516.

Yen SSc, Laughlin GA, Morales AJ. Interface beween extra-and intraovarian factors in human oocyte and subsequent embryonic development. J Reprod Med 2001;46:22–34.

Yoshimura Y, Wallach EE. Studies of the mechanism(s) of mammalian ovulation. Ann NY Acad Sci 1993;687:98–111.

Yeo CX, Gilchrist RB, Thompson JG, Lane M. Exogenous growth differentiation factor 9 in oocyte maturation media enhances subsequent embryo development and fetal viability in mice. Hum Reprod 2008;23:67–73.

Yildirim B, Demir S, Temur I, Erdemir R, Kaleli B. Lipid Peroxidation in follicular fluid of polycystic ovaries in patients treated with dexamethasone. Hum Reprod 2003;18:755–771.

Yin SSC, Laughlin GA, Morales AJ. Interface beween extra-and intraovarian factors in polycystic ovarian syndrome. Ann NY Acad Sci 1993;687:98–111.

Yu CJ, Chen CY, Chou SY, Lee CH, Tsai YL. Expression of growth differentiation factor 9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome. Fertil Steril 2010;94:261–267.

Zakli M, Bider D, Seddan MS, Mashiach S, Ben-Rafael Z. Cytokine levels in follicular fluid of polycystic ovaries treated with dexamethasone. Fertil Steril 1992;57:501–504.